CROI 21 (Retrovirus) 2014

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

Pharmacokinetics of antiretrovirals in pregnancy

Better virologic outcomes with efavirenz vs lopinavir/ritonavir in pregnant women and no difference in risk of preterm birth

Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents

Early antiretroviral treatment in infants

Hospitalisation among elite controllers

Catching up with pathogenesis and cure research from CROI 2014

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

ARV pipeline: doravirine, GSK-744 and BMS-068

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Pharmacokinetic targets for efavirenz might be too high

Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

Lower newborn bone mineral content with maternal tenofovir use

Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

Xpert TB test has important advantages but does not reduce morbidity

Reports of a second baby possibly cured of HIV: uncertainty remains

Updates on SB728-T, a CCR5-targeting gene therapy